Trimetazidine in conditions other than coronary disease, old drug, new tricks?. (1st May 2017)

• Record Type: Journal Article
• Authors: Zou, Hai; Zhu, Xing-Xing; Ding, Ya-Hui; Jin, Qin-Yang; Qian, Lin-Yan; Huang, Dong-Sheng; Cen, Xue-Jiang
• Is Part Of: International journal of cardiology. Volume 234(2017)
• Page Start: 1
• Page End: 6
• Publication Date: 2017-05-01
• Subjects: Trimetazidine -- Non-ischemic cardiomyopathy -- Sepsis -- Myocardial dysfunction induced by anti-cancer drugs -- Diabetic cardiomyopathy -- Contrast-induced nephropathy; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2017.02.083
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Trimetazidine (TMZ) has traditionally been used as an anti-ischemic drug for coronary artery disease by selectively inhibiting the mitochondrial long-chain 3-ketoacyl-CoA thiolase. Recently, new applications for this therapy have been investigated. This article reviews alternative uses for TMZ in non-coronary artery diseases, such as non-ischemic cardiomyopathy, sepsis, myocardial dysfunction induced by anti-cancer drugs, diabetic cardiomyopathy and contrast-induced nephropathy. Highlights: TMZ, acting as a potent antioxidant, regulates LV modelling and the progressive decline of contractile function in the normal evolution of DCM. TMZ significantly improve inflammation, membrane destruction and oxidative stress in sepsis. TMZ has been shown to protect against the toxicity of chemotherapeutic agents, used in the treatment of a variety of human cancers. Promising treatment with drugs in the patient with diabetic nephropathy. Recent initiatives to enhance the quality use of TMZ are an important strategy for the future health-care needs.